Furthermore, their results clearly demonstrated that if p53 stimulation is made in the context of increasing levels of VEGF (resulting in normal tumor progression), the patient’s condition worsens, while p53 stimulation in the context of using a topoisomerase I inhibitor results in increasing effectiveness of the cancer treatment—hence the major interest, but also the major concern in p53 modulation to control tumor progression. The gene discussed is VEGFA; the disease is neoplasm.